Ponatinib D8

• CAT Number: I017425
• CAS Number: 1562993-37-6
• Molecular Formula: C₂₉H₁₉D₈F₃N₆O
• Molecular Weight: 540.61
• Purity: ≥95%
• Target: Autophagy
• Storage: Store at -20°C
• IUPAC Name: 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(2,2,3,3,5,5,6,6-octadeuterio-4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide
• InChI: InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)/i12D2,13D2,14D2,15D2
• InChIKey: PHXJVRSECIGDHY-DHNBGMNGSA-N
• SMILES: [2H]C1(C(N(C(C(N1C)([2H])[2H])([2H])[2H])CC2=C(C=C(C=C2)NC(=O)C3=CC(=C(C=C3)C)C#CC4=CN=C5N4N=CC=C5)C(F)(F)F)([2H])[2H])[2H]

Ponatinib D8 is a deuterated form of Ponatinib, a tyrosine kinase inhibitor used in cancer treatment, specifically targeting chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). This compound features eight deuterium atoms, making it an invaluable tool for pharmacokinetic and metabolic studies. Ponatinib D8 is utilized as an internal standard in LC-MS/MS analysis, allowing for precise quantification of Ponatinib levels in biological samples. The stable isotope labeling enhances the accuracy and consistency of analytical results, supporting drug development, therapeutic monitoring, and research into the optimization of cancer therapies.